Seyed Amir Banikarim

Seyed Amir Banikarim

Auto-generated profile, based on publicly available information

Seyed Amir Banikarim

Hematology-Oncology Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2026 in Journal of Preventive Epidemiology
Verified
Journal Article
Open access
PDF file
KSKianoush Saberi
Kianoush Saberi
AOAtieh Okhli
Atieh Okhli
KRKhorsid Rigi
Khorsid Rigi
SBSeyed Amir Banikarim
Seyed Amir Banikarim
SJSara Teihou Jorshari
Sara Teihou Jorshari
SSShahnaz Sharifi
Shahnaz Sharifi
Aspirin, a widely used non-steroidal anti-inflammatory drug, has shown promise in cancer prevention and reducing metastatic progression. This medication limits platelet thromboxane A2 (TXA2)-mediated suppression of T-cell immunity, thereby preventing cancer metastasis. Platelets, beyond their role in hemostasis, actively contribute to tumor progression and metastasis by various mechanisms, including shielding circulating tumor cells from immune surveillance and promoting their extravasation. One critical pathway involves platelet-derived TXA2, a potent lipid mediator that can directly suppress anti-tumor T-cell responses. TXA2 promotes immune evasion by inhibiting T-cell activation and proliferation, thus hindering the body’s ability to effectively eliminate cancerous cells. Aspirin’s well-known inhibitory effect on cyclooxygenase-1 (COX-1) is key here, as COX-1 is responsible for TXA2 synthesis in platelets. By irreversibly acetylating COX-1, aspirin effectively reduces TXA2 production. Then, the reduction in platelet TXA2 alleviates its immunosuppressive effects on T-cells, thereby restoring and enhancing anti-tumor immunity. The enhanced T-cell activity can then more effectively target and destroy circulating tumor cells, finally limiting the formation of secondary tumors and preventing metastasis.

26 January 2026 in Journal of Nephropathology
Verified
Journal Article
Open access
PDF file
Sina Salem AhimSina Salem Ahim
Sina Salem Ahim
PSParadise Fatehi Shalamzari
Paradise Fatehi Shalamzari
FNFaezeh Nesaei
Faezeh Nesaei
FKFaezeh Khajeh
Faezeh Khajeh
SSSeyed Amir Sheikholeslami
Seyed Amir Sheikholeslami
NNNaeem Nikpour
Naeem Nikpour
Patients with systemic lupus erythematosus (SLE) exhibit a distinct cancer risk profile characterized by increased susceptibility to hematologic malignancies such as non-Hodgkin lymphoma (NHL), as well as certain solid tumors like lung, thyroid, and hepatobiliary cancers. Conversely, they also demonstrate a reduced risk for some cancers including breast, melanoma, and prostate cancer. This unique pattern is influenced by a combination of disease-related immune dysregulation and treatment-related factors. Additionally, immunosuppressive therapy administered in SLE management, including agents like cyclophosphamide, is known to contribute to an elevated risk of malignancies such as cervical dysplasia and certain hematologic cancers. However, specific immunosuppressants like calcineurin inhibitors have shown no significant increase in cancer incidence in some cohorts, suggesting that cancer risk is multifactorial and may depend on the type and duration of immunosuppression. However, in SLE patients, screening practices for cancers like cervical cancer are suboptimal despite their increased risk. However, some studies have found lower cervical cancer screening rates in women with SLE compared to control subjects, which influenced by factors like age, income, and comorbidities. Improved screening uptake is crucial for early cancer detection and better outcomes in this vulnerable population. Moreover, lupus nephritis enhances cancer risk and progression through complex interplay of chronic inflammation, immune dysregulation, treatment effects, and molecular pathway alterations. Inflammation-induced oxidative stress and impaired autophagy, combined with immunosuppressive therapies, provide a background for malignant transformation and decreased tumor immune surveillance.

19 April 2026 in Journal of Nephropathology
Verified
Journal Article
Open access
PDF file
MNMohammadreza Nowroozi
Mohammadreza Nowroozi
AKAli Khalilzadeh
Ali Khalilzadeh
SBSeyed Amir Banikarim
Seyed Amir Banikarim
HSHoushang Sanadgol
Houshang Sanadgol
RARasoul Jafari Arismani
Rasoul Jafari Arismani
NNNaeem Nikpour
Naeem Nikpour
Introduction: Kidney cancer is a common tumor of the urinary system, and existing data on the relationship between sodium–glucose cotransporter 2 (SGLT2) inhibitors use and kidney cancer are inconsistent. Therefore, this study aimed to investigate the association between SGLT2 inhibitor use and the risk of developing kidney cancer. Materials and Methods: This study was designed as a systematic review and meta-analysis following the PRISMA guidelines. Accordingly, a comprehensive search was conducted in the Cochrane, Scopus, Web of Science, Embase, and PubMed databases, as well as the Google Scholar search engine, up to January 5, 2026. Data analysis was performed using STATA version 14. Results: The results showed that the association between the use of SGLT2 inhibitors (OR: 1.14, 95% CI: 0.86–1.52), dapagliflozin (OR: 1.67, 95% CI: 0.47–5.93), canagliflozin (OR: 1.59, 95% CI: 0.61–4.15), and empagliflozin (OR: 1.31, 95% CI: 0.52–3.27) with the risk of kidney cancer was not statistically significant. However, SGLT2 inhibitor use was associated with a reduced risk of renal cell carcinoma (RCC) (OR: 0.69, 95% CI: 0.63–0.76). In contrast, compared with dipeptidyl peptidase‑4 (DPP‑4) inhibitors, SGLT2 inhibitor use was linked to an increased risk of kidney cancer (OR: 1.64, 95% CI: 1.11–2.43). Conclusion: In conclusion, the use of SGLT2 inhibitors did not affect the incidence of kidney cancer, but it was associated with a 31% reduction in the risk of RCC. In contrast, compared with DPP‑4 inhibitors, SGLT2 inhibitor use increased the risk of kidney cancer by 64%. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420261293668) and Research Registry (UIN; reviewregistry2078) websites.

28 March 2026 in Immunopathologia Persa
Verified
Journal Article
Closed access
ZKZahed Karimi
Zahed Karimi
SNSara Abutalebi Nasrabad
Sara Abutalebi Nasrabad
RFReza Farzaneh
Reza Farzaneh
SBSeyed Amir Banikarim
Seyed Amir Banikarim
FSFarkhondeh Sameipoor
Farkhondeh Sameipoor
NNNaeem Nikpour
Naeem Nikpour
The mechanistic sequence from hyperandrogenism to tumorigenesis in women with polycystic ovary syndrome (PCOS) encompasses a constellation of structural and functional aberrations spanning the endocrine, metabolic, immunologic, and genetic domains. Chronic hyperandrogenism incites an interconnected cascade through chronic anovulation and unopposed estrogen action, insulin resistance with hyperinsulinemia, low-grade systemic inflammation, oxidative stress, and gut dysbiosis, each playing a synergistic role in promoting oncogenesis. It has been demonstrated that, this syndrome is most strongly associated with an increased risk of endometrial cancer, with a more modest and less consistent association with ovarian and breast cancers. Thyroid cancer risk may also be elevated, particularly in younger women. The underlying mechanisms involve hormonal imbalances, metabolic dysfunction, chronic inflammation, and genetic predisposition. Women with PCOS should be monitored for early signs of these cancers, and management should focus on mitigating risk factors such as obesity, insulin resistance, and chronic anovulation.